Meropenem Pediatric Dosing
For pediatric patients ≥3 months with normal renal function, administer meropenem 20 mg/kg every 8 hours for complicated intra-abdominal infections and 10 mg/kg every 8 hours for complicated skin/soft tissue infections, with maximum doses of 1 gram and 500 mg respectively. 1
Standard Dosing by Age and Indication
Pediatric Patients ≥3 Months of Age
The FDA-approved dosing varies by infection type 1:
- Complicated skin/soft tissue infections (cSSSI): 10 mg/kg every 8 hours (maximum 500 mg per dose) 1
- Complicated intra-abdominal infections (cIAI): 20 mg/kg every 8 hours (maximum 1 gram per dose) 1
- Meningitis: 40 mg/kg every 8 hours (maximum 2 grams per dose) 1
- Pseudomonas aeruginosa cSSSI: Increase to 20 mg/kg every 8 hours (maximum 1 gram) 1
For children weighing >50 kg, use adult dosing: 500 mg every 8 hours for cSSSI, 1 gram every 8 hours for cIAI, and 2 grams every 8 hours for meningitis 1.
Guidelines support these carbapenem doses, recommending 60 mg/kg/day divided every 8 hours for pediatric complicated intra-abdominal infections 2.
Neonates and Infants <3 Months of Age
Dosing is based on gestational age (GA) and postnatal age (PNA) for complicated intra-abdominal infections 1:
- <32 weeks GA and PNA <2 weeks: 20 mg/kg every 12 hours 1
- <32 weeks GA and PNA ≥2 weeks: 20 mg/kg every 8 hours 1
- ≥32 weeks GA and PNA <2 weeks: 20 mg/kg every 8 hours 1
- ≥32 weeks GA and PNA ≥2 weeks: 30 mg/kg every 8 hours 1
For neonatal necrotizing enterocolitis, meropenem is an acceptable broad-spectrum option as part of combination therapy 2.
Administration
Administer as intravenous infusion over 15-30 minutes 1. Bolus injection over 3-5 minutes is acceptable for doses ≤1 gram, though safety data for 40 mg/kg bolus doses is limited 1. For neonates <3 months, infuse over 30 minutes 1.
Prolonged infusion (4 hours) may improve outcomes in neonates with Gram-negative late-onset sepsis, demonstrating higher clinical improvement, microbiologic eradication, lower mortality, and less acute kidney injury compared to conventional 30-minute infusions. 3 Extended infusions also improve pharmacokinetic target attainment in neonates with augmented creatinine clearance 4.
Renal Impairment Adjustments
Pediatric Patients with Renal Impairment
There is no established FDA dosing guidance for pediatric patients with renal impairment 1. However, recent pharmacokinetic modeling suggests dose reductions to 10 mg/kg for moderate renal impairment and 7.5 mg/kg for severe renal impairment 5.
For children with end-stage renal disease on prolonged intermittent renal replacement therapy (PIRRT), standard once-daily dosing is insufficient; PIRRT increases meropenem clearance by approximately 42.6%, requiring dose adjustments 6.
Adult Renal Impairment (for reference)
For creatinine clearance 26-50 mL/min: use standard dose every 12 hours 1. For CrCl 10-25 mL/min: use half the standard dose every 12 hours 1. For CrCl <10 mL/min: use half the standard dose every 24 hours 1.
Important Clinical Considerations
Monitor renal function closely during therapy, as meropenem clearance correlates strongly with renal function (correlation coefficient -0.7). 7 Dose-normalized meropenem exposure varies significantly across renal function categories 7.
Maximize β-lactam doses when undrained intra-abdominal abscesses may be present. 2 For bacteria with higher MICs (≥2 µg/mL), such as Pseudomonas aeruginosa, consider 40 mg/kg every 8 hours with prolonged infusion duration (4 hours) to achieve pharmacodynamic targets 8.
Current dosing may not reliably achieve pharmacokinetic targets (>50% time above MIC) in critically ill pediatric patients, particularly those with augmented renal clearance 9. Only 27.8% of critically ill patients achieved target trough concentrations >8 mg/L in one study 9.
Contraindicated in patients with known hypersensitivity to meropenem, other carbapenems, or β-lactams with anaphylactic reactions. 1